Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non - small-cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

abstract

  • Addition of ABT-751 to pemetrexed is well-tolerated, but does not improve outcome in unselected patients with recurrent NSCLC. ABT-751 may have therapeutic potential in squamous NSCLC. Exploratory cellular and molecular analyses in this study identified biomarkers that may correlate with survival.

publication date

  • March 10, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4672026

Digital Object Identifier (DOI)

  • 10.1200/JCO.2010.32.5944

PubMed ID

  • 21300929

Additional Document Info

start page

  • 1075

end page

  • 82

volume

  • 29

number

  • 8